Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Distribute Sera's PreTRM Test, Lead $40M Series C Round

NEW YORK (GenomeWeb) – Sera Prognostics said today it has tapped Laboratory Corporation of America to be the exclusive US distributor of Sera's PreTRM test for preterm birth.

Sera noted that LabCorp's existing non-invasive prenatal testing, women's healthcare, and reproductive genetics businesses make it well positioned to drive commercialization of the test.

"As a market leader in NIPT, women’s health and reproductive genetics, LabCorp brings a significant depth of experience that will help expand the commercialization of PreTRM," Sera Chairman and CEO Gregory Critchfield added in a statement.

The PreTRM test measures the levels of two proteins in blood to predict a pregnant woman's risk of giving preterm birth. Sera launched the test in a limited release last year and plans to make it available nationwide in 2017 through the LabCorp collaboration.

LabCorp will also lead a $40 million Series C funding round for Sera, the proceeds of which the company will use to collect clinical data to support reimbursement and expand commercial availability of PreTRM nationwide.

Financial and other terms of the agreement were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.